Results 121 to 130 of about 377,838 (168)

Maternal Dipyrone Exposure and Risk of Major Congenital Malformations, Adverse Perinatal and Postnatal Outcomes: A Population‐Based Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pain and fever are common in pregnancy. Dipyrone is widely used in Europe, Latin America, and parts of Asia, but is banned in other countries due to concerns about agranulocytosis. Evidence on its safety in pregnancy remains limited and inconsistent. This study aimed to evaluate whether maternal dipyrone use during the first‐ and third‐trimesters is ...
Itamar Ben Shitrit, Daphna Idan, Ariel Avraham Hasidim, Tal Michael, Amalia Levy, Gali Pariente, Eitan Lunenfeld, Sharon Daniel   +7 more
wiley   +1 more source

Loss of POGLUT2/3‐mediated O‐glucosylation produces lung and aortic phenotypes reminiscent of fibrillin1 mutants

Developmental Dynamics, EarlyView.
Abstract Background Fibrillins provide a scaffold for elastic fiber formation, which enables lung recoil and aortic compliance. Abnormal fibrillin microfibrils, as in Marfan syndrome, lead to enlarged alveoli, vascular stiffening, and aneurysms. Our earlier studies suggested that fibrillin function depends on O‐glucosylation of its epidermal growth ...
Sanjiv Neupane, Angelina Almiroudis, Kaitlyn E. Donnelly, Robert S. Haltiwanger, Bernadette C. Holdener   +4 more
wiley   +1 more source

Characteristics of Respiratory Microbiome in COPD-A Literature Review. [PDF]

Adv Respir Med
Ciesielska-Markowska I, Mycroft-Rzeszotarska K, Korczyński P, Pulik K, Górska K.   +4 more
europepmc   +1 more source

Human Metapneumovirus and Its Association With Otorhinolaryngological Manifestations: A Systematic Review With Descriptive Synthesis

Eye &ENT Research, EarlyView.
ABSTRACT Human metapneumovirus (HMPV) is a respiratory virus that predominantly affects the pediatric population. Its role as an infective agent in ear, nose, and throat (ENT) diseases is not yet well understood. To systematically review the available literature on the association between HMPV and ENT manifestations, following PRISMA guidelines, a ...
Ali Gohar, Muhammad Husnain Ahmad, Hamza Zaheer, Fizza Inam, Moeez Ahmad Saeed, Nimra Mehmood, Abdul Rehman Shahid Khan, Alishbah Saeed, Hanzala Zahid, Yashika Gupta, Muhammad Bilal Akram, Habban Ghani, Muhammad Ahmad Farooq   +12 more
wiley   +1 more source

Association of Frailty and Frailty Trajectory with Risk for Respiratory Infectious Diseases. [PDF]

Emerg Infect Dis
Yang J, Yan H, Chen H, Liu D, Li Z, Mao C.   +5 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Frailty Increases the Risk and Frequency of Lower Respiratory Tract Infections in Older Adults: A Multicenter Prospective Cohort Study. [PDF]

Open Forum Infect Dis
Zhang Q, Gu X, Chang K, Ni Y, Wang C, Zi J, Zhao B, Zou X, Cao B.   +8 more
europepmc   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

<i>Mycoplasma pneumoniae</i>-associated Central Nervous System Manifestations: Current Knowledge and Challenges. [PDF]

Open Forum Infect Dis
Akinnurun OM, Dumke R.
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source